Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Eric Zhou
In Vitro Susceptibility of HCV Genotype 1 Through 6 Clinical Isolates to the Pan-Genotypic NS3/4A Inhibitor Voxilaprevir
Journal of Clinical Microbiology
Microbiology
Related publications
HCV NS3/4A Protein Complex
Science-Business eXchange
Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172
In Vitro Antiviral Profile of Ruzasvir: A Potent and Pan-Genotype Inhibitor of HCV NS5A
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era?
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era? Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Drug Resistance Against HCV NS3/4A Inhibitors Is Defined by the Balance of Substrate Recognition Versus Inhibitor Binding
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Sofosbuvir and Velpatasvir: A Complete Pan-Genotypic Treatment for HCV Patients
Turkish Journal of Gastroenterology
Gastroenterology
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Gastroenterology
Hepatology
Gastroenterology
